Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT00757757 | A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | terminated | Phase 1 / Phase 2 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02911467 | Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer(MR) | terminated | Phase 1 | 8 | Rahul AggarwalOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 12 | Pellficure Pharmaceuticals, IncINDUSTRY | 1 | Mar 9, 2020 | clinicaltrials |
| NCT03043989 | Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00702923 | CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | terminated | Phase 1 | 12 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02500901 | Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) | terminated | Phase 1 | 2 | Paul Mathew, MDOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00124917 | Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer | terminated | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT01741753 | BKM120+Abiraterone Acetate for Metastatic CRPC | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02478125 | Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01262664 | A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01647789 | A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 3, 2018 | clinicaltrials |
| NCT01983709 | Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer(MSC) | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer(Prostate-04) | terminated | Phase 1 | 2 | James Larner, MDOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT00096304 | Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 36 | Medical University of South CarolinaOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT02349139 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 27 | Asana BioSciencesINDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02606123 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | ESSA PharmaceuticalsINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
| NCT00004261 | EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | terminated | Phase 1 | — | University Health Network, TorontoOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01677845 | Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer | terminated | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01642732 | Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer | terminated | Phase 1 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02429804 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT01155791 | Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | terminated | Phase 1 | 2 | Sandy SrinivasOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01913197 | Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy | terminated | Phase 1 / Phase 2 | 2 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT00933426 | Lenalidomide and Paclitaxel in Prostate Cancer | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT00861471 | Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT00503984 | A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 22 | University of MiamiOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT00023634 | S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer | terminated | Phase 1 | 14 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00005072 | Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
| NCT00976508 | Figitumumab Combined With Pegvisomant For Advanced Solid Tumors | terminated | Phase 1 | 24 | PfizerINDUSTRY | 4 | Dec 13, 2013 | clinicaltrials |
| NCT00010127 | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 3 | Duke UniversityOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00005067 | Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00512668 | Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00288444 | Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer | terminated | Phase 1 | 38 | Emory UniversityOTHER | 1 | Dec 18, 2012 | clinicaltrials |
| NCT00293371 | Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Oct 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jan 27, 2021source: clinicaltrials